CHRAC15 Activators
CHRAC15 activators principally comprise compounds geared towards altering the chromatin landscape, given CHRAC15's intrinsic role in chromatin remodeling. Leading the assembly is Trichostatin A, renowned for its histone deacetylase inhibition. Its influence on chromatin structure could usher in conditions favorable for CHRAC15 activation. Following closely are Valproic Acid and 5-Azacytidine, the former being another agent influencing histone deacetylation, and the latter, a DNA methyltransferase, emphasizing the dual nature of chromatin regulation – both through histones and DNA itself.
In the vast realm of chromatin, the spectrum of histone deacetylase is vast. Sodium Butyrate, Vorinostat, Mocetinostat, Romidepsin, Panobinostat, Belinostat, and Entinostat all fall under this umbrella. Each, in its unique way, modulates the chromatin structure, ensuring a dynamic environment. This ever-changing nature of chromatin can bring CHRAC15 into action. Tacedinaline and MGCD0103 further amplify this concept, again underscoring the importance of histone acetylation in chromatin dynamics. Collectively, these agents underscore the intricacies of chromatin remodeling and highlight the indirect avenues through which CHRAC15 can be activated.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor, can facilitate chromatin remodeling which may indirectly stimulate CHRAC15 functionality. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
By inhibiting histone deacetylase, it can influence chromatin state and potentially impact CHRAC15. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor, promotes DNA demethylation and chromatin opening, possibly affecting CHRAC15's role. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Acts as a histone deacetylase inhibitor, can change chromatin conformation potentially activating CHRAC15. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
By inhibiting histone deacetylases, it can alter chromatin dynamics potentially impacting CHRAC15. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
As a histone deacetylase inhibitor, it can alter chromatin structure potentially affecting CHRAC15's activity. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
Can modify chromatin state by inhibiting histone deacetylases, thereby possibly impacting CHRAC15 indirectly. | ||||||
CI 994 | 112522-64-2 | sc-205245 sc-205245A | 10 mg 50 mg | $97.00 $525.00 | 1 | |
Histone deacetylase inhibitor can impact chromatin structure, possibly influencing CHRAC15. | ||||||